<DOC>
	<DOCNO>NCT02459938</DOCNO>
	<brief_summary>The purpose study determine whether glucagon administer microneedle patch comparable glucagon administer injection pen treatment insulin-induced hypoglycemia .</brief_summary>
	<brief_title>Safety Efficacy ZP-Glucagon Injectable Glucagon Hypoglycemia</brief_title>
	<detailed_description>The purpose study compare ZP-Glucagon transdermal patch system dose 0.5 mg 1 mg glucagon injection dose 0.5 mg 1 mg mean 4 way crossover open label design . Eligible subject give informed consent randomise treatment sequence four treatment one week interval . At treatment visit , subject undergo insulin induction procedure design safely induce hypoglycemia , treatment apply , either injection patch , monitor return normoglycemia .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Women men 18 60 year type1 diabetes daily insulin treatment ( basalbolus injection regimen insulin pump ) least two year , total daily dose stable last 3 month precede enrollment ( 20 % variation ) , current level glycated hemoglobin 6.5 % 10 % Any history hypoglycemic coma hypoglycemic seizure . Any episode severe hypoglycemia ( require treatment ) within one month prior study start . Any history pheochromocytoma insulinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>